Our finding that blockade of the TLR4–NF-κB pathway or TNF-α can reverse impaired myogenesis suggests a new set of drug targets for clinical intervention in sepsis- or metabolic endotoxemia-induced muscle debilitation. The gene discussed is TLR4; the disease is Sepsis.